Tove Wästerlid (Former)

1 – 10 of 11

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/98fbb726-91b2-4b9a-8ace-eb2c7443869f?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
next »

2024
Mark The National Swedish Lymphoma Register – a systematic validation of data quality
Smedby, Karin E. ; Eloranta, Sandra ; Wästerlid, Tove ^LU ; Falini, Victor ^LU ; Jerlström, Urban ; Ellin, Fredrik ^LU ; Papworth, Karin ; Westerberg, Johanna ; Lewerin, Catharina and Andersson, Per Ola , et al. (2024) In Acta Oncologica 63. p.563-572
- Contribution to journal › Article
2022
Mark Application of precision medicine in clinical routine in haematology—Challenges and opportunities
Wästerlid, Tove ^LU ; Cavelier, Lucia ; Haferlach, Claudia ; Konopleva, Marina ; Fröhling, Stefan ; Östling, Päivi ; Bullinger, Lars ; Fioretos, Thoas ^LU and Smedby, Karin E. (2022) In Journal of Internal Medicine 292(2). p.243-261
- Contribution to journal › Scientific review
2020
Mark Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
Wästerlid, Tove ^LU ; Harrysson, Sara ; Andersson, Therese M.L. ; Ekberg, Sara ; Enblad, Gunilla ; Andersson, Per Ola ; Jerkeman, Mats ^LU ; Eloranta, Sandra and Smedby, Karin E. (2020) In American Journal of Hematology 95(7). p.740-748
- Contribution to journal › Article
Mark Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients
Jakobsen, Lasse H. ; Ellin, Fredrik ^LU ; Smeland, Knut B. ; Wästerlid, Tove ^LU ; Christensen, Jacob H. ; Jørgensen, Judit M. ; Josefsson, Pär L. ; Øvlisen, Andreas K. ; Holte, Harald and Blaker, Yngvild N. , et al. (2020) In British Journal of Haematology 189(4). p.661-671
- Contribution to journal › Article
2019
Mark Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
Wästerlid, T. ^LU ; Mohammadi, M. ; Smedby, K. E. ; Glimelius, I. ; Jerkeman, M. ^LU ; Bottai, M. and Eloranta, S. (2019) In Journal of Internal Medicine 285(4). p.455-468
- Contribution to journal › Article
2017
Mark Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
Wästerlid, Tove ^LU ; Nordström, Lena ^LU ; Freiburghaus, Catja ^LU ; Pedersen, Mette ; Nørgaard, Peter ; Gang, Anne O. ; Brown, Peter ; Dictor, Michael ^LU ; Jerkeman, Mats ^LU and Ek, Sara ^LU (2017) In Leukemia & Lymphoma 58(7). p.1760-1763
- Contribution to journal › Letter
2016
Mark Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
Wästerlid, Tove ^LU (2016)
- Thesis › Doctoral thesis (compilation)
Mark Högintensiv cytostatikaterapi ökade överlevnad vid burkitts lymfom
Wästerlid, Tove ^LU (2016) In Läkartidningen 113(48).
- Contribution to journal › Article
2015
Mark Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
Wästerlid, Tove ^LU ; Werner Hartman, Linda ^LU ; Szekely, Erzsébet ^LU and Jerkeman, Mats ^LU (2015) In Hematological Oncology
- Contribution to journal › Article
2013
Mark Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
Wästerlid, Tove ^LU ; Brown, P N ; Hagberg, Oskar ^LU ; Hagberg, H ; Pedersen, L M ; D'Amore, F and Jerkeman, Mats ^LU (2013) In Annals of Oncology 24(7). p.1879-1886
- Contribution to journal › Article

« previous
1
2
next »